NCT07053358View on ClinicalTrials.gov

Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 2, 2025

Primary Completion Date

November 23, 2026

Study Completion Date

December 30, 2029

Conditions
Neovascular Age-related Macular Degeneration
Interventions
GENETIC

LX111 Injection

Qualified subjects will receive a single unilateral intravitreal injection of LX111 at Day 0.

Trial Locations (1)

200080

RECRUITING

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

Sponsors
All Listed Sponsors
collaborator

Innostellar Biotherapeutics Co.,Ltd

INDUSTRY

lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER